POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
125 hedge funds and large institutions have $411M invested in POINT Biopharma Global Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 51 increasing their positions, 38 reducing their positions, and 18 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 38
4% less funds holding
Funds holding: 130 → 125 (-5)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
28% less capital invested
Capital invested by funds: $571M → $411M (-$160M)
41% less call options, than puts
Call options by funds: $1.55M | Put options by funds: $2.64M
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$9.1M |
| 2 |
Millennium Management
New York
|
+$7.08M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$3.71M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$3.46M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$2.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$15.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.48M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$7.64M |
| 4 |
Goldman Sachs
New York
|
-$5.96M |
| 5 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$3.11M |
PNT Hedge Fund Activity: Q3 2023 in Review
125 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q3 2023, worth a combined $411M — down 28% from $571M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PNT and 13 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 51 added.
The largest buyer was Bellevue Group, adding an estimated $9.1M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $15.1M sold.
- 125 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q3 2023, down from 130 in Q2 2023.
- Funds reported $411M of POINT Biopharma Global Inc. Common Stock stock for Q3 2023, down 28% quarter-over-quarter.
- 13 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q3 2023 and 18 closed out, a net change of -5 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q3 2023 was Bellevue Group, an estimated $9.1M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q3 2023 was Avidity Partners Management, an estimated $15.1M sold.
Based on aggregated 13F filings for Q3 2023.